New data show XEPLION® significantly delays time to relapse compared to treatment as usual with oral antipsychotic monotherapy
- EMEA
- XEPLION® Significantly Delays Time to Relapse with Oral Antipsychotic Monotherapy
New data show XEPLION® significantly delays time to relapse compared to treatment as usual with oral antipsychotic monotherapy